ACM
DRNA

Aquilo Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Aquilo Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,456,595
Closed -$49.5M – 16
2021
Q3 		$49.5M Buy
2,456,595
+643,203
+35% +$17.8M 8.99% 4
2021
Q2 		$67.7M Buy
1,813,392
+108,000
+6% +$3.31M 17.58% 1
2021
Q1 		$43.6M Buy
1,705,392
+350,000
+26% +$8.94M 7.88% 4
2020
Q4 		$29.9M Sell
1,355,392
-19,384
-1% -$427K 6.21% 6
2020
Q3 		$24.7M Sell
1,374,776
-79,910
-5% -$1.65M 2.62% 5
2020
Q2 		$36.9M Buy
1,454,686
+217,307
+18% +$4.68M 7.45% 2
2020
Q1 		$22.7M Buy
1,237,379
+622,943
+101% +$12.1M 8.86% 3
2019
Q4 		$13.5M Buy
+614,436
New +$12.4M 5.08% 8

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Aquilo Capital Management's DRNA Position: Q4 2021 in Review

Aquilo Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 2,456,595 shares — an estimated $49.5M sold.

Aquilo Capital Management first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $67.7M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Aquilo Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Aquilo Capital Management sold 2,456,595 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $49.5M.
  • Aquilo Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
  • Aquilo Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $67.7M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Aquilo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.